Bayer cancels asundexian phase III study programme : vimarsa

Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. Read more at straitstimes.com.

Related Keywords

Xia Fxia , Data Monitoring Committee , Reuters , Independent Data Monitoring Committee ,